Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure

Respirology

Volumn 18, Issue 1, 2013, Pages 125-130

  Boschetto, Piera ^a   Fucili, Alessandro ^a   Stendardo, Mariarita ^a   Malagù, Michele ^a   Parrinello, Giovanni ^b   Casimirri, Enrico ^a   Potena, Alfredo ^a   Ballerin, Licia ^a   Fabbri, Leonardo M ^c   Ferrari, Roberto ^a   Ceconi, Claudio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

chronic heart failure; chronic obstructive pulmonary disease; elderly; functional capacity; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTERIAL OXYGEN TENSION; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; CREATININE BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SPIROMETRY; SURVIVAL;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 84871839432     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02264.x     Document Type: Article

References (29)

1. Stewart S, MacIntyre K, Capewell S, et al,. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003; 89: 49-53.
2. Fabbri LM, Luppi F, Beghé B, et al,. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31: 204-12.
3. Hawkins NM, Petrie MC, Jhund PS, et al,. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur. J. Heart Fail. 2009; 11: 130-9.
4. Rutten FH, Cramer MJ, Lammers JW, et al,. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur. J. Heart Fail. 2006; 8: 706-11.
5. Dickstein K, Cohen-Solal A, Filippatos G, et al,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail. 2008; 10: 933-89.
6. Rabe KF, Hurd S, Anzueto A, et al,. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-55.
7. Miller MR, Hankinson J, Brusasco V, et al,. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-38.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39: S1-266.
9. Lang RM, Bierig M, Devereux RB, et al,. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440-63.
10. Quiñones MA, Otto CM, Stoddard M, et al,. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 2002; 15: 167-84.
11. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-7.
12. Charlson ME, Sax FL,. The therapeutic efficacy of critical care units from two perspectives: a traditional cohort approach vs a new case-control methodology. J. Chronic Dis. 1987; 40: 31-9.
13. Akaike H,. A new look at the statistical model identification. IEEE Trans. Automat. Contr. 1974; 19: 716-23.
14. R Development Core Team. R: A Language and Environment for Statistical Computing. The R Foundation for Statistical Computing, Vienna, 2011. Available from URL: http://www.R-project.org/.
15. Quanjer PH, Tammeling G, Cotes JE, et al,. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. 1993; 6 (Suppl. 16): 5-40.
16. Mascarenhas J, Lourenço P, Lopes R, et al,. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am. Heart J. 2008; 155: 521-5.
17. Hawkins NM, Jhund PS, Simpson CR, et al,. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur. J. Heart Fail. 2010; 12: 17-24.
18. Macchia A, Monte S, Romero M, et al,. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur. J. Heart Fail. 2007; 9: 942-8.
19. Rusinaru D, Saaidi I, Godard S, et al,. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am. J. Cardiol. 2008; 101: 353-8.
20. Hawkins NM, Huang Z, Pieper KS, et al,. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur. J. Heart Fail. 2009; 11: 292-8.
21. Staszewsky L, Wong M, Masson S, et al,. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J. Card. Fail. 2007; 13: 797-804.
22. Chapman KR, Mannino DM, Soriano JB, et al,. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 188-207.
23. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al,. Unrecognised ventricular dysfunction in COPD. Eur. Respir. J. 2012; 39: 51-8.
24. Inoue Y, Kawayama T, Iwanaga T, et al,. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern. Med. 2009; 48: 503-12.
25. Braunstein JB, Anderson GF, Gerstenblith G, et al,. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J. Am. Coll. Cardiol. 2003; 42: 1226-33.
26. De Blois J, Simard S, Atar D, et al,. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J. Card. Fail. 2010; 16: 225-9.
27. O'Kelly N, Robertson W, Smith J, et al,. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J. Cardiol. 2012; 4: 66-71.
28. Sin DD, McAlister FA,. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am. J. Med. 2002; 113: 650-6.
29. Lee DS, Mamdani MM, Austin PC, et al,. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am. J. Med. 2004; 116: 581-9.